Savara Inc.
SVRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Savara Inc. (SVRA) is listed under Biotechnology. At a $1.08B market cap, Savara Inc. ranks as a small-cap company within healthcare. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Market Cap
$1.08B
Beta
0.28
P/E (TTM)
—
P/E (Fwd)
-14.48
EPS (TTM)
$-0.56
EPS (Fwd)
$-0.36
ROE
-80.0%
ROA
-40.5%
Cash
$204.1M
Total Debt
$30.1M
Free CF
-$57.7M
52W Change
110.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $204.1M in cash comfortably exceeding the $30.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$57.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -80.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.28 suggests SVRA is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing SVRA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.